Silexion
Sector:
Pharma/Biotech
Subsector:
Oncology
Geography:
Israel
Regulatory status:
Clinical Trials
Back
A clinical stage biopharmaceutical company that is developing proprietary RNA interference (RNAi)-based cancer drugs and a specific delivery system designed to effectively penetrate and treat malignant solid tumors, including pancreatic cancer.